Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 3,100 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $49.68, for a total value of $154,008.00. Following the completion of the transaction, the insider now directly owns 42,246 shares in the company, valued at approximately $2,098,781.28. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total transaction of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.19, for a total transaction of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total value of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total value of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.02, for a total value of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total transaction of $164,889.00.

RxSight Price Performance

RXST stock opened at $48.51 on Thursday. The company has a 50 day moving average price of $52.08 and a 200 day moving average price of $53.82. RxSight, Inc. has a fifty-two week low of $20.66 and a fifty-two week high of $66.54. The stock has a market capitalization of $1.79 billion, a PE ratio of -38.50 and a beta of 1.20.

RxSight (NASDAQ:RXST) last released its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The company had revenue of $34.89 million during the quarter, compared to the consensus estimate of $32.33 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. The firm’s quarterly revenue was up 67.6% on a year-over-year basis. As a group, equities analysts expect that RxSight, Inc. will post -0.81 earnings per share for the current fiscal year.

Institutional Trading of RxSight

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new stake in shares of RxSight during the 1st quarter worth approximately $1,929,000. Principal Financial Group Inc. grew its holdings in RxSight by 298.5% during the 1st quarter. Principal Financial Group Inc. now owns 34,928 shares of the company’s stock worth $1,802,000 after acquiring an additional 26,164 shares during the period. Baillie Gifford & Co. bought a new stake in shares of RxSight during the 1st quarter valued at $3,429,000. M&G Plc acquired a new position in shares of RxSight in the 1st quarter valued at $7,354,000. Finally, Inspire Investing LLC bought a new position in shares of RxSight in the 1st quarter worth $917,000. 78.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Wells Fargo & Company decreased their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus dropped their price objective on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. BTIG Research boosted their target price on RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Oppenheimer dropped their price target on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $60.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.